Radius's bone-building drug positive in Phase II trials
This article was originally published in Scrip
Executive Summary
Radius Health's novel bone-building drug BA058 has tested positively in Phase II trials, increasing the odds that Novartis will choose to exercise a potential $500 million option to acquire rights.